INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2010

Grapefruit consumption is linked to potentially fatal drug interactions involving CYP3A4, while also offering benefits for diabetes and cardiovascular disorders.

This review evaluates metabolic and cardiovascular perspectives related to grapefruit consumption. Grapefruit or grapefruit juice consumption is associated with drug interactions—some fatal—mediated by intestinal CYP3A4, P-glycoprotein, and organic cation transporter proteins. Concurrently, grapefruit's rich flavonoid content has emerged as beneficial in managing degenerative conditions like diabetes and cardiovascular disorders, though the clinical extent of its drug interactions remains not fully determined.

Study type
Review
Who was studied
Not specified
What was measured
Drug interactions and metabolic/cardiovascular effects

THE PAPER

The grapefruit: an old wine in a new glass? Metabolic and cardiovascular perspectives.

Owira PM, Ojewole JA. Cardiovasc J Afr, 2010.

PubMed 20972517 ↗DOI 10.5830/cvja-2010-012 ↗

Heart & arteriesDiabetes & blood sugarFood safety & contaminantsTop 21: Oranges & citrus

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.